Literature DB >> 18426732

Overexpression of AIB1 in nasopharyngeal carcinomas correlates closely with advanced tumor stage.

Meng-Zhong Liu1, Dan Xie, Shi-Juan Mai, Zhu-Ting Tong, Jian-Yong Shao, Yong-Shui Fu, Wen-Jie Xia, Hsian-Fu Kung, Xin-Yuan Guan, Yi-Xin Zeng.   

Abstract

AIB1, a candidate oncogene in breast cancer, is commonly amplified and overexpressed in several types of human cancers. In this study, expression and amplification of AIB1 in nasopharyngeal carcinoma (NPC) were studied by immunohistochemical analysis and fluorescence in situ hybridization using tissue microarrays, including 80 specimens of NPC and 20 specimens of nonneoplastic nasopharyngeal mucosa. In this NPC cohort, overexpression and amplification of AIB1 was detected in 36 (51%) of 71 and 3 (7%) of 46 NPCs, respectively. Overexpression of AIB1 was observed more frequently in NPCs in late T stages (T3/T4, 24/35 [69%]) than in earlier stages (T1/T2, 12/36 [33%]; P < .05). In addition, 18 (72%) of 25 NPCs with lymph node metastasis (N1-3) showed overexpression of AIB1; the frequency was significantly higher than that in NPCs without node metastasis (N0, 18/49 [39%]; P < .05). These findings suggest that overexpression of AIB1 in NPCs may be important in the acquisition of an invasive and/or metastatic phenotype.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18426732     DOI: 10.1309/QMDTL82JKEX6E7H2

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  13 in total

1.  AIB1 as an independent prognostic marker in hepatocellular carcinoma after hepatic resection.

Authors:  Jun-Min Song; Min Lu; Fang-Fang Liu; Xiao-Juan Du; Bao-Cai Xing
Journal:  J Gastrointest Surg       Date:  2011-11-04       Impact factor: 3.452

2.  The AIB1 gene polyglutamine repeat length polymorphism and the risk of breast cancer development.

Authors:  Zdenek Kleibl; Ondrej Havranek; Stanislav Kormunda; Jan Novotny; Lenka Foretova; Eva Machackova; Jana Soukupova; Marketa Janatova; Spiros Tavandzis; Petr Pohlreich
Journal:  J Cancer Res Clin Oncol       Date:  2010-04-27       Impact factor: 4.553

3.  Overexpression of AIB1 correlates inversely with E-cadherin expression in pancreatic adenocarcinoma and may promote lymph node metastasis.

Authors:  Si Guo; JingJing Xu; Rui Xue; YuQiong Liu; HaiBo Yu
Journal:  Int J Clin Oncol       Date:  2013-03-30       Impact factor: 3.402

Review 4.  Nuclear receptor coactivators: structural and functional biochemistry.

Authors:  Yaroslava A Bulynko; Bert W O'Malley
Journal:  Biochemistry       Date:  2010-12-29       Impact factor: 3.162

5.  Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.

Authors:  Junko Suzuki; Yunn-Yi Chen; Gary K Scott; Sandy Devries; Koei Chin; Christopher C Benz; Frederic M Waldman; E Shelley Hwang
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

6.  Up-regulation of nuclear receptor coactivator amplified in breast cancer-1 in papillary thyroid carcinoma correlates with lymph node metastasis.

Authors:  M-Y Liu; H-P Guo; C-Q Hong; H-W Peng; X-H Yang; H Zhang
Journal:  Clin Transl Oncol       Date:  2013-04-20       Impact factor: 3.405

Review 7.  Steroid receptor coactivator-3 as a potential molecular target for cancer therapy.

Authors:  Jean Ching-Yi Tien; Jianming Xu
Journal:  Expert Opin Ther Targets       Date:  2012-08-27       Impact factor: 6.902

Review 8.  SRC-3, a Steroid Receptor Coactivator: Implication in Cancer.

Authors:  Licen Li; Chu-Xia Deng; Qiang Chen
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

Review 9.  SRC-3 has a role in cancer other than as a nuclear receptor coactivator.

Authors:  Gang Ma; Yu Ren; Ke Wang; Jianjun He
Journal:  Int J Biol Sci       Date:  2011-05-24       Impact factor: 6.580

10.  AIB1 predicts bladder cancer outcome and promotes bladder cancer cell proliferation through AKT and E2F1.

Authors:  Z-T Tong; J-H Wei; J-X Zhang; C-Z Liang; B Liao; J Lu; S Fan; Z-H Chen; F Zhang; H-H Ma; W-C Qian; L-L Kong; Y Fang; W Chen; D Xie; J-H Luo
Journal:  Br J Cancer       Date:  2013-03-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.